Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US

References

• GLOBOCAN 2012 v.1.1. International Agency for Research on Cancer (IARC), World Health Organization, Lyon, France. Available at: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx [Last accessed 14 August 2017]
   Google Scholar
• Fitzmaurice C, Akinyemiju TF, Al Lami FH, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol 2018. Jun 2. doi: 10.1001/jamaoncol.2018.2706. [Epub ahead of print]
   Web of Science ®Google Scholar
• About non-small cell lung cancer. American Cancer Society, 2016. Available at: https://www.cancer.org/content/dam/CRC/PDF/Public/8703.00.pdf [Last accessed 14 August 2017
   Google Scholar
• Chen VW, Ruiz BA, Hsieh MC, et al. Analysis of stage and clinical/prognostic factors for lung cancer from SEER registries: AJCC staging and collaborative stage data collection system. Cancer 2014;120(Suppl 23):3781-92
   PubMed Web of Science ®Google Scholar
• Abernethy AP, Arunachalam A, Burke T, et al. Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting. PLoS One 2017;12:e0178420
   PubMed Web of Science ®Google Scholar
• Highlights of prescribing information. KEYTRUDA (pembrolizumab) injection, for intravenous use. Merck & Co., Inc.; 2017
   Google Scholar
• Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 2016;17:1497-508
   PubMed Web of Science ®Google Scholar
• Borghaei H, Langer CJ, Gadgeel SM, et al. 24-Month overall survival from KEYNOTE-021 cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced Nnonsquamous non-small-cell lung cancer. J Thorac Oncol 2018;In Press
   Web of Science ®Google Scholar
• Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018;378:2078-92
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47
   PubMed Web of Science ®Google Scholar
• Keytruda (MK-3475) HTA report. Indication: First-line metastatic non-squamous NSCLC with strongly positive PD-L1. Indirect treatment comparison. Pembrolizumab in combination with chemotherapy versus pembrolizumab monotherapy. Scenario 1: proportional hazards. Merck data on file. March 8, 2018
   Google Scholar
• Keytruda (MK-3475) HTA report. Indication: First-line metastatic non-squamous NSCLC with strongly positive PD-L1. Indirect treatment comparison. Pembrolizumab monotherapy versus pembrolizumab in combination with chemotherapy. Scenario 2: non-proportional hazards. Merck data on file. March 8, 2018
   Google Scholar
• Neumann PJ, Sanders GD, Russell LB, et al., editors. Cost-effectiveness in health and medicine. 2nd edition. New York, NY: Oxford University Press; 2016
   Google Scholar
• Latimer N. NICE DSU technical support document 14: Survival analysis for economic evaluations alongside clinical trials – extrapolation with patient-level data. Sheffield: Report by the Decision Support Unit; 2011. Available at: http://docplayer.net/11340696-Nice-dsu-technical-support-document-14-survival-analysis-for-economic-evaluations-alongside-clinical-trials-extrapolation-with-patient-level-data.html [Last accessed 28 March 18]
   Google Scholar
• Latimer NR, Abrams KR. NICE DSU technical support document 16: adjusting survival time estimates in the presence of treatment switching. NICE; 2014. Available at: http://www.nice.dsu.org.uk/TSD16_Treatment_Switching.pdf
   Google Scholar
• Latimer NR. Survival analysis for economic evaluations alongside clinical trials—extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med Decis Making 2013;33:743-54
   PubMed Web of Science ®Google Scholar
• Surveillance Research Program. National Cancer Institute SEER*Stat software. Version 8.3.4, April 14, 2017. Rockville, MD. Available at: seer.cancer.gov/seerstat [Last accessed 22 October 2017]
   Google Scholar
• Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016;375:1823-33
   PubMed Web of Science ®Google Scholar
• Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91
   PubMed Web of Science ®Google Scholar
• Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011;46:399-424
   PubMed Web of Science ®Google Scholar
• Allgemeine Methoden. Institute for quality and efficiency in healthcare (IQWiG). Version 5.0. Allgemeine Methoden; 2017
   Google Scholar
• National Cancer Institute. Common terminology criteria for adverse events (CTCAE) Version 4.0. NCI; 2009 (v4.03: 2010)
   Google Scholar
• Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 2005;43:203-20
   PubMed Web of Science ®Google Scholar
• Hatswell AJ, Pennington B, Pericleous L, et al. Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death. Health Qual Life Outcomes 2014;12:140
   PubMed Web of Science ®Google Scholar
• Huang M, Lou Y, Pellissier J, et al. Cost effectiveness of pembrolizumab vs standard-of-care chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in the United States. Pharmacoeconomics 2017;35:831-44
   PubMed Web of Science ®Google Scholar
• U.S. Bureau of Labor Statistics. Consumer price index: medical care–all urban consumers. 2017. Available at: http://www.bls.gov/cpi/
   Google Scholar
• www.analysource.com, February 2018
   Google Scholar
• Center for Medicare and Medicaid Services. Cost procedural terminology, fourth edition. Costs for hospital outpatient services, by HCPCS code for CY. CMMS; 2016. Baltimore, MD.
   Google Scholar
• FY 2018 IPPS Final Rule. Centers for Medicare and Medicaid Services; 2018. Baltimore, MD. Available at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/FY2018-IPPS-Final-Rule-Home-Page.html. [Last accessed 28 February 2018]
   Google Scholar
• GDP per capita (current US$). World Bank national accounts data, and OECD National Accounts data files. 2018. Available at: https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?order=wbapi_data_valu. Washington D.C.
   Google Scholar
• Bertram MY, Lauer JA, De Joncheere K, et al. Cost-effectiveness thresholds: pros and cons. Bull World Health Organ 2016;94:925-30
   PubMed Web of Science ®Google Scholar
• Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2013;31:2895-902
   PubMed Web of Science ®Google Scholar
• Goeree R, Villeneuve J, Goeree J, et al. Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes. J Med Econ 2016;19:630-44
   PubMed Web of Science ®Google Scholar
• Coyle D, Coyle K. The inherent bias from using partitioned survival models in economic evaluation. Value Health 2014;17:A194
   Web of Science ®Google Scholar
• Beca J, Hoch J. Exploring the impact of structural uncertainty in partitioned survival models for oncology. Value Health 2014;17:A205-6
   PubMed Web of Science ®Google Scholar